137 related articles for article (PubMed ID: 18363346)
1. A mutual prodrug ester of GABA and perphenazine exhibits antischizophrenic efficacy with diminished extrapyramidal effects.
Nudelman A; Gil-Ad I; Shpaisman N; Terasenko I; Ron H; Savitsky K; Geffen Y; Weizman A; Rephaeli A
J Med Chem; 2008 May; 51(9):2858-62. PubMed ID: 18363346
[TBL] [Abstract][Full Text] [Related]
2. BL-1020: a novel antipsychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia.
Geffen Y; Nudelman A; Gil-Ad I; Rephaeli A; Huang M; Savitsky K; Klapper L; Winkler I; Meltzer HY; Weizman A
Eur Neuropsychopharmacol; 2009 Jan; 19(1):1-13. PubMed ID: 18757185
[TBL] [Abstract][Full Text] [Related]
3. BL-1020, an oral antipsychotic agent that reduces dopamine activity and enhances GABAA activity, for the treatment of schizophrenia.
Fitzgerald PB
Curr Opin Investig Drugs; 2010 Jan; 11(1):92-100. PubMed ID: 20047163
[TBL] [Abstract][Full Text] [Related]
4. An open-label tolerability study of BL-1020 antipsychotic: a novel gamma aminobutyric acid ester of perphenazine.
Anand R; Geffen Y; Vasile D; Dan I
Clin Neuropharmacol; 2010; 33(6):297-302. PubMed ID: 20921890
[TBL] [Abstract][Full Text] [Related]
5. BL-1020, a novel antipsychotic candidate with GABA-enhancing effects: D2 receptor occupancy study in humans.
Appel L; Geffen Y; Heurling K; Eriksson C; Antoni G; Kapur S
Eur Neuropsychopharmacol; 2009 Dec; 19(12):841-50. PubMed ID: 19717284
[TBL] [Abstract][Full Text] [Related]
6. 7-[3-(1-piperidinyl)propoxy]chromenones as potential atypical antipsychotics.
Bolós J; Gubert S; Anglada L; Planas JM; Burgarolas C; Castelló JM; Sacristán A; Ortiz JA
J Med Chem; 1996 Jul; 39(15):2962-70. PubMed ID: 8709130
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and evaluation of the antipsychotic potential of orally bioavailable neurotensin (8-13) analogues containing non-natural arginine and lysine residues.
Hadden MK; Orwig KS; Kokko KP; Mazella J; Dix TA
Neuropharmacology; 2005 Dec; 49(8):1149-59. PubMed ID: 16095636
[TBL] [Abstract][Full Text] [Related]
8. [Vacuous chewing after haloperidol and GABA-linoleamide administration in the rat].
Vamvakidès A
Agressologie; 1986 Nov; 27(10):819-21. PubMed ID: 3812899
[No Abstract] [Full Text] [Related]
9. Chlorzoxazone esters of some non-steroidal anti-inflammatory (NSAI) carboxylic acids as mutual prodrugs: design, synthesis, pharmacological investigations and docking studies.
Abdel-Azeem AZ; Abdel-Hafez AA; El-Karamany GS; Farag HH
Bioorg Med Chem; 2009 May; 17(10):3665-70. PubMed ID: 19398345
[TBL] [Abstract][Full Text] [Related]
10. Progesterone attenuates neuroleptic-induced orofacial dyskinesia via the activity of its metabolite, allopregnanolone, a positive GABA(A) modulating neurosteroid.
Bishnoi M; Chopra K; Kulkarni SK
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):451-61. PubMed ID: 17988775
[TBL] [Abstract][Full Text] [Related]
11. Fluphenazine decanoate and tardive dyskinesia.
Schiff AA
Am J Psychiatry; 1982 Jul; 139(7):969-70. PubMed ID: 6124136
[No Abstract] [Full Text] [Related]
12. Antischizophrenic drugs and brain cholinergic receptors. Affinity for muscarinic sites predicts extrapyramidal effects.
Snyder S; Greenberg D; Yamamura HI
Arch Gen Psychiatry; 1974 Jul; 31(1):58-61. PubMed ID: 4152054
[No Abstract] [Full Text] [Related]
13. Diminished neurocardiac dynamics associated with antipsychotic-induced extrapyramidal syndrome.
Kim JH; Yi SH; Park KT; Ahn YM; Lee KY; Yang SA; Kim YS
Eur Neuropsychopharmacol; 2006 Aug; 16(6):459-63. PubMed ID: 16343860
[TBL] [Abstract][Full Text] [Related]
14. [Arousal inhibiting and catalepsy in neuroleptic drugs].
Stille G
Arzneimittelforschung; 1966 Feb; 16(2):255-6. PubMed ID: 6013811
[No Abstract] [Full Text] [Related]
15. [Effect of GABA-linoleamide and glycine-linoleamide on catalepsy in the rat after chronic administration of reserpine].
Vamvakidès A
Agressologie; 1986 Nov; 27(10):835-7. PubMed ID: 3028195
[No Abstract] [Full Text] [Related]
16. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). Position of the pharmacologist. From neuroleptics to non-neuroleptic antipsychotics].
Costentin J
Encephale; 2009 Jan; Suppl 3():S119-22. PubMed ID: 19268181
[No Abstract] [Full Text] [Related]
17. Evaluation of amphetamine-induced hyperlocomotion and catalepsy following long-acting risperidone administration in rats.
Marchese G; Casu G; Casti P; Spada GP; Pani L
Eur J Pharmacol; 2009 Oct; 620(1-3):36-41. PubMed ID: 19664616
[TBL] [Abstract][Full Text] [Related]
18. [Effect of 3 new GABA-ergics on reserpine catalepsy and apomorphine sedation in rats].
Vamvakidès A
Agressologie; 1987 May; 28(5):535-9. PubMed ID: 3661856
[No Abstract] [Full Text] [Related]
19. Synthesis and Characterization of new Azecine-Derivatives as Potential Neuroleptics.
Zergiebel S; Fleck C; Arndt HD; Enzensperger C; Seeling A
Drug Res (Stuttg); 2017 Aug; 67(8):466-475. PubMed ID: 28521372
[TBL] [Abstract][Full Text] [Related]
20. [The neuroleptic efficiency of some butyrophenone and fluorinated phenothiazine derivatives (author's transl)].
Bekemeier H; Krause E
Pharmazie; 1980; 35(10):634-7. PubMed ID: 6109310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
